LG Chem 
Welcome,         Profile    Billing    Logout  
 39 Products   109 Diseases   39 Products   42 Trials   1950 News 


«12...56789101112131415...2021»
  • ||||||||||  Zemimet SR (gemigliptin/metformin sustained release) / LG Chem, NN1213 / Novo Nordisk
    Trial completion, Trial completion date, Combination therapy:  INTESTINE: Initial Combination of Gemigliptin and Metformin on Microbiota Change (clinicaltrials.gov) -  Mar 30, 2021   
    P=N/A,  N=70, Completed, 
    In conclusion, polynucleotide sodium could effectively reduce weight-bearing pain in the patients with knee osteoarthritis compared to standard hyaluronic acid viscosupplementation. Active, not recruiting --> Completed | Trial completion date: Dec 2021 --> Mar 2021
  • ||||||||||  Xospata (gilteritinib) / Astellas, Fotivda (tivozanib) / AVEO, Jazz
    [VIRTUAL] Cytoplasmic Expression of XPO7 Distinguishes a Subset of Ovarian Carcinoma Vulnerable to SLK Inhibition () -  Mar 26, 2021 - Abstract #SSO2021SSO_102;    
    Treatment of XPO7:SLK expressing human and mouse OC cell lines with two kinase inhibitors with activity against SLK – tivozanib and gilteritinib – abrogated tumorsphere formation in vitro. We have identified XPO7 as a biomarker for aggressive disease in OC and provide evidence for therapeutic targeting of SLK with small molecule kinase inhibitors in XPO7 expressing tumors.
  • ||||||||||  Follitrope (recombinant human follicle stimulating hormone) / LG Chem
    Enrollment change, Trial completion date, Trial primary completion date:  MSP-IVC: Minimal Stimulation Protocol Using Aromek(Letrozole) and Follitrope(recFSH) Combined With INVOCell-Low Cost IVF (clinicaltrials.gov) -  Mar 24, 2021   
    P=N/A,  N=30, Recruiting, 
    We have identified XPO7 as a biomarker for aggressive disease in OC and provide evidence for therapeutic targeting of SLK with small molecule kinase inhibitors in XPO7 expressing tumors. N=100 --> 30 | Trial completion date: Feb 2012 --> Mar 2022 | Trial primary completion date: Dec 2011 --> Dec 2021
  • ||||||||||  Avastin (bevacizumab) / Roche
    Review, Journal:  A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer. (Pubmed Central) -  Mar 23, 2021   
    In this review, we have assessed studies focused upon the treatment of non-small cell lung cancer. Some therapies are approved, such as bevacizumab and atezolizumab, while some are still in clinical trials, such as ficlatuzumab and ipilimumab, and others have been rejected due to inadequate disease control, such as figitumumab.
  • ||||||||||  Adalimumab BS MA (adalimumab biosimilar) / Mochida, LG Chem, Daewoong Pharma
    Trial completion:  A Study Comparing LBAL to Humira (clinicaltrials.gov) -  Mar 15, 2021   
    P3,  N=383, Completed, 
    The larger and longer follow-up will be essential to determine these beneficial effects. Active, not recruiting --> Completed
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    [VIRTUAL] Tyrosine kinome profiling of renal cell carcinoma (RCC) () -  Mar 11, 2021 - Abstract #AACR2021AACR_1510;    
    Furthermore, we have demonstrated different inhibitory effects of TKIs ex-vivo and identified two peptide clusters significantly affected by TKI. Further analysis of affected kinases and signaling pathways as well as correlations with clinical data for the same group of patients will be performed.
  • ||||||||||  Zemimet SR (gemigliptin/metformin sustained release) / LG Chem
    Trial completion, Enrollment change, Trial completion date:  Bioequivalence Study for Fixed Dose Combination Zemimet (clinicaltrials.gov) -  Feb 9, 2021   
    P1,  N=40, Completed, 
    In summary, our study indicates that Follitrope Prefilled Syringe is safe and efficacious for ovarian stimulation. Not yet recruiting --> Completed | N=60 --> 40 | Trial completion date: Dec 2020 --> Sep 2020
  • ||||||||||  Fotivda (tivozanib) / AVEO, Jazz
    Preclinical, Journal:  Brain accumulation of tivozanib is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein) in mice. (Pubmed Central) -  Jan 29, 2021   
    Oral plasma pharmacokinetics of tivozanib was not significantly altered in these mouse strains, nor in Cyp3a knockout and CYP3A4-humanized mice. The modest effect of ABC transporters on tivozanib brain accumulation, if also true in humans, might mean that this drug is not strongly limited in its therapeutic efficacy against malignant lesions situated partly or completely behind the blood-brain barrier.
  • ||||||||||  CUE-101 / Cue Biopharma
    Journal:  CUE-101, a Novel HPV16 E7-pHLA-IL-2-Fc Fusion Protein, Enhances Tumor Antigen Specific T Cell Activation for the Treatment of HPV16-Driven Malignancies. (Pubmed Central) -  Jan 28, 2021   
    P1
    The modest effect of ABC transporters on tivozanib brain accumulation, if also true in humans, might mean that this drug is not strongly limited in its therapeutic efficacy against malignant lesions situated partly or completely behind the blood-brain barrier. Consistent with its design, CUE-101 demonstrates selective expansion of an HPV16 E7-specific population of cytotoxic CD8T cells, a favorable safety profile, and in vitro and in vivo evidence supporting its potential for clinical efficacy in an ongoing Phase 1 trial (NCT03978689).